Decrease in Pharma Business Drives Response Genetics' Q3 Revenues Down 10 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Driven by a downswing in revenues from its pharmaceutical clients, Response Genetics today said that third-quarter revenues dipped 10 percent year over year to $5.1 million.

Revenues for the three months ended Sept. 30 compare to $5.6 million for the third quarter a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.